High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
A R
AR
Zander
W
W
Krüger
N
N
Kröger
L
L
Damon
M
M
Königmann
W E
WE
Berdel
F
F
Gieseking
K
K
Schäfer-Eckart
V
V
Möbus
N
N
Frickhofen
H
H
Wandt
H J
HJ
Illiger
B
B
Metzner
K
K
Kolbe
B
B
Wörmann
L
L
Trümper
C
C
Huber
D K
DK
Hossfeld
H
H
Maass
W
W
Jonat
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005858:Germany; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D009367:Neoplasm Staging; D013852:Thiotepa / Q000008:administration & dosage / Q000009:adverse effects; D014182:Transplantation, Autologous
D003520:Cyclophosphamide; D013852:Thiotepa; D008942:Mitoxantrone